



Pfizer Australia Pty Ltd  
Level 17, 151 Clarence Street  
Sydney, NSW 2000

12 December 2022

Dear Healthcare Professional,

**Shelf-life extension of PAXLOVID™ (nirmatrelvir 150 mg/ritonavir 100 mg), film coated tablets  
AUST R 377572**

We would like to inform you that on 17 November 2022 a new shelf life for PAXLOVID has been approved in Australia by the Therapeutic Goods Administration (TGA).

The shelf life has been extended from 18 months to 24 months. The storage condition of 'Store below 25 degrees Celsius' remains unchanged.

This extension of the shelf life may be applied retrospectively to PAXLOVID batches manufactured prior to this approval. Cartons with an expiry date of August 2022 through to December 2023 printed on the carton or blisters may remain in use for a longer period beyond the printed expiry date, as long as the approved storage conditions have been maintained.

PAXLOVID is a co-packaged product consisting of nirmatrelvir and ritonavir tablets, which could have different production dates. For this reason, the updated expiry date cannot be calculated by adding 6 months or 12 months to the printed expiry date (that was determined based on the shelf life approved at the time of manufacturing) and must be determined by identifying the specific batch number in the list below:

<u>Batch Number</u>	<u>Printed Date</u>	<u>Updated Expiry Date</u>
FT4565; FT4889	08/2022	07/2023
FT5412	11/2022	07/2023
FT9972	12/2022	07/2023
FX7183; FX7184	01/2023	09/2023
FY1869; FY1870; FY1866; FY1871; FY1868; FY1872; FY1874	02/2023	11/2023
GA8046; GA8765; A8771; GC2932; GC2916	02/2023	01/2024
GD4586; GD4587; GD3145; GC8173; GD4572	03/2023	01/2024
GD1179; GD1180	03/2023	11/2023
GC0803; GC5724; GC0805; GD1182; GC0806	03/2023	12/2023
GD1184; GC5725; GC5722	03/2023	02/2024
GC5729; GD1189	04/2023	02/2024

GJ2966; GJ2970; GJ2969; GJ2968; GJ2967	11/2023	03/2024
GJ2959; GJ7302; GJ2963; GJ2961; GJ2960; GJ2962	12/2023	03/2024

**PLEASE REVIEW THE CURRENT AUSTRALIAN PRODUCT INFORMATION BEFORE PRESCRIBING OR DISPENSING.**

The Australian Product Information and Consumer Medicine Information can be found at <https://www.tga.gov.au/>. The PAXLOVID Australian Product Information for Healthcare professionals is also available by scanning the QR Code below:



**Adverse Event Reporting**



PAXLOVID is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems). Alternatively, any adverse events which are experienced with PAXLOVID can be reported to Pfizer on 1800 675 229 or by email to [AUS.AEReporting@pfizer.com](mailto:AUS.AEReporting@pfizer.com)

**Medical Enquiries**

Please direct any medical enquiries to Medical Information on 1800 675 229 or via [www.pfizermedicalinformation.com.au](http://www.pfizermedicalinformation.com.au)

Yours sincerely,

*Krishan*

**Dr Krishan Thiru**  
Medical Director  
Pfizer Australia